
DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target
DENTSPLY SIRONA (XRAY) Analyst Ratings
Bulls say
Dentsply Sirona has demonstrated positive sales performance, with a reported sales growth of 2.8% in Europe and a 1.8% organic growth, indicating resilience in its core markets. Additionally, the company is poised for accelerating revenue growth in the mid-single digits over the coming years, supported by potential drivers such as a recovery in the implants segment and market share gains in clear aligners. Furthermore, Wellspect Healthcare's strong revenue generation, which exceeded expectations and grew 6.7% organically, highlights Dentsply Sirona's capability to enhance margins and overall earnings performance.
Bears say
Dentsply Sirona's recent financial performance has been characterized by significant underperformance, exemplified by an adjusted EPS of $0.26 that fell short of expectations by a substantial margin. Additionally, the connected technology solutions (CTS) segment experienced an 8.3% decline in revenue, compounded by increased operating expenses and a gross margin decrease of 240 basis points year-over-year, which further strained profitability. The impact of the Byte shutdown resulted in a notable loss of $62 million in revenue and a $0.24 reduction in adjusted EPS, contributing to a negative outlook for the company's financial health amid restructuring and integration challenges.
This aggregate rating is based on analysts' research of DENTSPLY SIRONA and is not a guaranteed prediction by Public.com or investment advice.
DENTSPLY SIRONA (XRAY) Analyst Forecast & Price Prediction
Start investing in DENTSPLY SIRONA (XRAY)
Order type
Buy in
Order amount
Est. shares
0 shares